EXG202
Phase 2Biologic
EXG202 is one of 32 biologic programs targeting Neovascular AMD. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Tecfidera
BiogenApproved
Bayer Aspirin
BayerApproved
Zometa
PfizerApproved
Plavix
SanofiApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EXG202. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- GGuangzhou Jiayin Biotech Ltd